SG11202104307VA - Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha - Google Patents
Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alphaInfo
- Publication number
- SG11202104307VA SG11202104307VA SG11202104307VA SG11202104307VA SG11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA SG 11202104307V A SG11202104307V A SG 11202104307VA
- Authority
- SG
- Singapore
- Prior art keywords
- ifn
- amide
- alpha
- modulation
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752414P | 2018-10-30 | 2018-10-30 | |
| PCT/US2019/058268 WO2020092196A1 (en) | 2018-10-30 | 2019-10-28 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104307VA true SG11202104307VA (en) | 2021-05-28 |
Family
ID=68582450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104307VA SG11202104307VA (en) | 2018-10-30 | 2019-10-28 | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230020273A1 (en) |
| EP (1) | EP3873892A1 (en) |
| JP (1) | JP7489381B2 (en) |
| KR (1) | KR20210086674A (en) |
| AU (1) | AU2019373203A1 (en) |
| BR (1) | BR112021007861A2 (en) |
| CA (1) | CA3118094A1 (en) |
| EA (1) | EA202191142A1 (en) |
| IL (1) | IL282840A (en) |
| MX (1) | MX2021004562A (en) |
| SG (1) | SG11202104307VA (en) |
| WO (1) | WO2020092196A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021195360A1 (en) * | 2020-03-27 | 2021-09-30 | Landos Biopharma, Inc. | Plxdc2 ligands |
| KR20230004771A (en) * | 2020-04-28 | 2023-01-06 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted N-(methyl-D3)pyridazine-3-carboxamide or N-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNalpha modulators |
| CN113773262A (en) * | 2020-06-09 | 2021-12-10 | 江苏先声药业有限公司 | Pyridazine compound |
| WO2022121868A1 (en) * | 2020-12-08 | 2022-06-16 | 正大天晴药业集团股份有限公司 | Tyk2 inhibitor compound containing amide group and heterocycloalkyl group |
| TW202233600A (en) * | 2021-02-06 | 2022-09-01 | 大陸商正大天晴藥業集團股份有限公司 | TYK2 inhibitor compound containing bicyclic ring |
| CA3213816A1 (en) * | 2021-03-16 | 2022-09-22 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CA3218579A1 (en) | 2021-05-14 | 2022-11-17 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
| WO2022253333A1 (en) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | Amide compounds and application thereof |
| WO2022253335A1 (en) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | Sulfonyl-containing aryl compound and application thereof |
| CN117500796A (en) * | 2021-06-22 | 2024-02-02 | 南京明德新药研发有限公司 | Sulfinimides and application thereof |
| CN117794911A (en) * | 2021-07-15 | 2024-03-29 | 南京明德新药研发有限公司 | Sulfur/phosphorus-containing aryl compounds and their use |
| EP4387964A1 (en) * | 2021-08-21 | 2024-06-26 | Relay Therapeutics, Inc. | Jak2 inhibitors and methods of use thereof |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| WO2024015497A1 (en) * | 2022-07-14 | 2024-01-18 | Biogen Ma Inc. | Tyrosine kinase 2 inhibitors and uses thereof |
| WO2024044486A1 (en) * | 2022-08-22 | 2024-02-29 | Ajax Therapeutics, Inc. | Jak2 inhibitor compounds |
| WO2024102683A1 (en) * | 2022-11-08 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted heterocyclic compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2890929A1 (en) * | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn.alpha. responses |
| MA38072A1 (en) * | 2012-11-08 | 2016-07-29 | Bristol Myers Squibb Co | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and / or responses to IFN? |
| AR094537A1 (en) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
-
2019
- 2019-10-28 MX MX2021004562A patent/MX2021004562A/en unknown
- 2019-10-28 AU AU2019373203A patent/AU2019373203A1/en active Pending
- 2019-10-28 KR KR1020217016043A patent/KR20210086674A/en unknown
- 2019-10-28 WO PCT/US2019/058268 patent/WO2020092196A1/en unknown
- 2019-10-28 JP JP2021523833A patent/JP7489381B2/en active Active
- 2019-10-28 CA CA3118094A patent/CA3118094A1/en active Pending
- 2019-10-28 EP EP19805033.8A patent/EP3873892A1/en active Pending
- 2019-10-28 US US17/289,269 patent/US20230020273A1/en active Pending
- 2019-10-28 SG SG11202104307VA patent/SG11202104307VA/en unknown
- 2019-10-28 EA EA202191142A patent/EA202191142A1/en unknown
- 2019-10-28 BR BR112021007861-4A patent/BR112021007861A2/en unknown
-
2021
- 2021-05-02 IL IL282840A patent/IL282840A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020092196A1 (en) | 2020-05-07 |
| EP3873892A1 (en) | 2021-09-08 |
| KR20210086674A (en) | 2021-07-08 |
| US20230020273A1 (en) | 2023-01-19 |
| MX2021004562A (en) | 2021-06-15 |
| JP2022506445A (en) | 2022-01-17 |
| EA202191142A1 (en) | 2021-07-20 |
| JP7489381B2 (en) | 2024-05-23 |
| BR112021007861A2 (en) | 2021-08-03 |
| AU2019373203A1 (en) | 2021-06-10 |
| CN113227071A (en) | 2021-08-06 |
| CA3118094A1 (en) | 2020-05-07 |
| IL282840A (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282840A (en) | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha | |
| IL271149A (en) | Compounds for modulating s1p1 activity and methods of using the same | |
| IL281277A (en) | Compositions and methods for the treatment of viral infections | |
| GB201820450D0 (en) | Compound and its use for the treatment of alpha1-antitryspin deficiency | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| IL271863B (en) | Compounds and use thereof for the treatment of microbial infections | |
| IL284414A (en) | Methods and compositions for the treatment of fabry disease | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| IL276482A (en) | Compounds for the treatment of pain | |
| IL276363A (en) | Combination of sting agonist and il-15/il15-ra for the treatment of cancer | |
| IL272121A (en) | Composition and methods for the treatment of myopia | |
| ZA202007320B (en) | Compounds for pain treatment, compositions comprising same, and methods of using same | |
| IL280218A (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| IL276228A (en) | Compounds and compositions for the treatment of pain | |
| IL280262A (en) | Compositions and methods for the treatment of cancer | |
| PL3618806T3 (en) | Compositon for the treatment of aphthas and mouth ulcers | |
| EP3604310A4 (en) | Cdc-7-inhibitor compounds and use thereof for the treatment of neurological conditions | |
| SG11202105593QA (en) | Substance for treatment or prevention of diseases, method for designing the same, and method for preparing the same | |
| SG11202105591UA (en) | Substance for treatment or prevention of diseases, method for designing the same, and method for preparing the same | |
| GB2574944B (en) | Methods and compositions for the treatment of pain and/or inflammation | |
| IL278984A (en) | Safinamide for treating myotonia | |
| GB201820451D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820455D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency | |
| GB201820452D0 (en) | Compounds and their use for the treatment of alpha1-antitryspin deficiency |